TY - JOUR
T1 - HLA-Haploidentical Stem Cell Transplantation for Hematologic Malignancies
AU - Fuchs, Ephraim J.
AU - Huang, Xiao jun
AU - Miller, Jeffrey S.
N1 - Publisher Copyright:
© 2017
PY - 2010/1
Y1 - 2010/1
N2 - Partially HLA-mismatched related, or HLA-haploidentical, donor stem cell transplantation (SCT) is a feasible therapeutic option for advanced hematologic malignancies patients who lack an HLA-matched related or unrelated donor. Advances in conditioning regimens, graft manipulation, and pharmacologic prophylaxis of graft-versus-host disease (GVHD) have reduced the risk of fatal graft failure and severe GVHD, two of the most serious complications of traversing the HLA barrier. Clinical observations reveal a potential role for natural killer (NK) cell alloreactivity in reducing the risk of relapse of acute myeloid leukemia after HLA-haploidentical SCT. NK cell infusions attempt to harness the graft-versus-leukemia effect without producing GVHD. The availability of multiple potential HLA-haploidentical related donors for most patients opens the possibility of optimizing transplantation outcome through intelligent donor selection.
AB - Partially HLA-mismatched related, or HLA-haploidentical, donor stem cell transplantation (SCT) is a feasible therapeutic option for advanced hematologic malignancies patients who lack an HLA-matched related or unrelated donor. Advances in conditioning regimens, graft manipulation, and pharmacologic prophylaxis of graft-versus-host disease (GVHD) have reduced the risk of fatal graft failure and severe GVHD, two of the most serious complications of traversing the HLA barrier. Clinical observations reveal a potential role for natural killer (NK) cell alloreactivity in reducing the risk of relapse of acute myeloid leukemia after HLA-haploidentical SCT. NK cell infusions attempt to harness the graft-versus-leukemia effect without producing GVHD. The availability of multiple potential HLA-haploidentical related donors for most patients opens the possibility of optimizing transplantation outcome through intelligent donor selection.
KW - Adoptive immunotherapy
KW - Graft-versus-host disease
KW - Human leukocyte antigens
KW - Natural killer cells
KW - Stem cell transplantation
KW - Transplantation conditioning
UR - http://www.scopus.com/inward/record.url?scp=77953074172&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953074172&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2009.10.032
DO - 10.1016/j.bbmt.2009.10.032
M3 - Article
C2 - 19892024
AN - SCOPUS:77953074172
SN - 1083-8791
VL - 16
SP - S57-S63
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 1
ER -
